ABP 234

Phase 3Small molecule

Amgen

ABP 234 is one of 277 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

276

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Vascular DiseaseActive, not recruiting

LymphomaPhase 3

Active, not recruiting

Metastatic MelanomaPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

PsoriasisPhase 3

Active, not recruiting

Age-Related Macular DegenerationPhase 3

Active, not recruiting

Vascular DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

ABP 234

Amgen

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Zolymbus

AbbVie

Preclinical

1 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Vfend

PPrism Pharmaceuticals

Paracetamol

1 9

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Pembrolizumab

NCT06430866

Q4 2027

Phase 3Recruiting

MPA

NCT06700343

Q1 2028

Phase 3Active, not recruiting

Metastatic Melanoma

NCT06054555

Q2 2028

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT06311721

Clinical

Trials by Indication[1]

Rheumatoid Arthritis4 trials

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Completed· Amgen logo

Amgen·Phase 3·NCT01970475·526 enrolled

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Completed· Amgen logo

Amgen·Phase 3·NCT02792699·311 enrolled

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

Completed· Amgen logo

Amgen·Phase 3·NCT02937701·558 enrolled

Show 1 more trial

Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

Completed· Amgen logo

Amgen·Phase 3·NCT02114931·467 enrolled

Psoriasis4 trials

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT05073315·425 enrolled

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT04607980·563 enrolled

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT01970488·350 enrolled

Show 1 more trial

A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT04761627·494 enrolled

Non-Small Cell Lung Cancer3 trials

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06311721·315 enrolled

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Withdrawn· Amgen logo

Amgen·Phase 3·NCT04466917

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT01966003·642 enrolled

Adalimumab2 trials

Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05995691·179 enrolled

A Randomized, Single-blind, Single-dose, 2-arm, Parallel-group Study to Determine the Pharmacokinetic Comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 mL (ABP 501-LCF) in Healthy Adult Subjects

Completed· Amgen logo

Amgen·Phase 1·NCT05909852·372 enrolled

Vascular Disease1 trial

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Completed· Amgen logo

Amgen·Phase 3·NCT05704725·49 enrolled

8 more indications

Metastatic Melanoma1 trial

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06054555·633 enrolled

Efficacy and Safety1 trial

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

Completed· Amgen logo

Amgen·Phase 3·NCT03818607·42 enrolled

Lymphoma1 trial

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

Completed· Amgen logo

Amgen·Phase 3·NCT02747043·256 enrolled

Breast Cancer1 trial

Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT01901146·725 enrolled

Melanoma1 trial

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Completed· Amgen logo

Amgen·Phase 3·NCT05907122·256 enrolled

Age-Related Macular Degeneration1 trial

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Completed· Amgen logo

Amgen·Phase 3·NCT04270747·576 enrolled

MPA1 trial

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Recruiting· Amgen logo

Amgen·Phase 3·NCT06700343·444 enrolled

Pembrolizumab1 trial

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Recruiting· Amgen logo

Amgen·Phase 3·NCT06430866·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for ABP 234. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABP 234 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABP 234. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Amgen

ABP 234

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Rheumatoid Arthritis4 trials

Psoriasis4 trials

Non-Small Cell Lung Cancer3 trials

Adalimumab2 trials

Vascular Disease1 trial

Metastatic Melanoma1 trial

Efficacy and Safety1 trial

Lymphoma1 trial

Breast Cancer1 trial

Melanoma1 trial

Age-Related Macular Degeneration1 trial

MPA1 trial

Pembrolizumab1 trial

References

Drug Info

Quick Facts

Related News